#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2. Obesity
1-1	0-2	2.	_	_	_	_
1-2	3-10	Obesity	abstract	new	coref	4-3

#Text=Before Liver Transplantation
2-1	11-17	Before	_	_	_	_
2-2	18-23	Liver	object|event[3]	new|new[3]	coref	14-7
2-3	24-39	Transplantation	event[3]	new[3]	_	_

#Text=2.1 .
3-1	40-43	2.1	abstract	new	_	_
3-2	44-45	.	_	_	_	_

#Text=How Should Obesity be Defined in Patients with Cirrhosis Considered for LT ?
4-1	46-49	How	_	_	_	_
4-2	50-56	Should	_	_	_	_
4-3	57-64	Obesity	abstract	giv	coref	5-7
4-4	65-67	be	_	_	_	_
4-5	68-75	Defined	_	_	_	_
4-6	76-78	in	_	_	_	_
4-7	79-87	Patients	person[6]	new[6]	coref	5-26[0_6]
4-8	88-92	with	person[6]	new[6]	_	_
4-9	93-102	Cirrhosis	person[6]|abstract	new[6]|new	coref	8-11[49_0]
4-10	103-113	Considered	_	_	_	_
4-11	114-117	for	_	_	_	_
4-12	118-120	LT	abstract	new	coref	8-29
4-13	121-122	?	_	_	_	_

#Text=The first obstacle is to define obesity in this population . Elamparast et al. recently summarized the most commonly used definitions in this group of patients :
5-1	123-126	The	abstract[9]	new[9]	_	_
5-2	127-132	first	abstract[9]	new[9]	_	_
5-3	133-141	obstacle	abstract[9]	new[9]	_	_
5-4	142-144	is	_	_	_	_
5-5	145-147	to	_	_	_	_
5-6	148-154	define	_	_	_	_
5-7	155-162	obesity	abstract	giv	coref	9-17[58_0]
5-8	163-165	in	_	_	_	_
5-9	166-170	this	abstract[11]	new[11]	coref	6-7[18_11]
5-10	171-181	population	abstract[11]	new[11]	_	_
5-11	182-183	.	_	_	_	_
5-12	184-194	Elamparast	_	_	_	_
5-13	195-197	et	_	_	_	_
5-14	198-201	al.	_	_	_	_
5-15	202-210	recently	_	_	_	_
5-16	211-221	summarized	_	_	_	_
5-17	222-225	the	abstract[12]	new[12]	_	_
5-18	226-230	most	abstract[12]	new[12]	_	_
5-19	231-239	commonly	abstract[12]	new[12]	_	_
5-20	240-244	used	abstract[12]	new[12]	_	_
5-21	245-256	definitions	abstract[12]	new[12]	_	_
5-22	257-259	in	abstract[12]	new[12]	_	_
5-23	260-264	this	abstract[12]|person[13]	new[12]|new[13]	_	_
5-24	265-270	group	abstract[12]|person[13]	new[12]|new[13]	_	_
5-25	271-273	of	abstract[12]|person[13]	new[12]|new[13]	_	_
5-26	274-282	patients	abstract[12]|person[13]|person	new[12]|new[13]|giv	coref	8-9[48_0]
5-27	283-284	:	_	_	_	_

#Text=- BMI ≥ 30 kg/m2 ( Asian population : ≥25 kg/m2 ) ; -
6-1	285-286	-	_	_	_	_
6-2	287-290	BMI	organization|quantity[16]	new|new[16]	appos|coref	6-4[17_16]|8-4
6-3	291-292	≥	quantity[16]	new[16]	_	_
6-4	293-295	30	quantity[17]	giv[17]	appos	6-10[19_17]
6-5	296-301	kg/m2	quantity[17]	giv[17]	_	_
6-6	302-303	(	_	_	_	_
6-7	304-309	Asian	abstract[18]	giv[18]	_	_
6-8	310-320	population	abstract[18]	giv[18]	_	_
6-9	321-322	:	_	_	_	_
6-10	323-326	≥25	quantity[19]	giv[19]	coref	18-11[0_19]
6-11	327-332	kg/m2	quantity[19]	giv[19]	_	_
6-12	333-334	)	_	_	_	_
6-13	335-336	;	_	_	_	_
6-14	337-338	-	_	_	_	_

#Text=Percentage of fat mass ≥28 % in men and ≥40 % in women ; - Waist circumference ˃102 cm in men and ˃88 cm in women ( Asian population : A waist circumference ˃90 cm in men and ˃80 cm in women ) ; - Visceral fat area ≥100 cm2 on abdominal computed tomography .
7-1	339-349	Percentage	abstract[20]	new[20]	_	_
7-2	350-352	of	abstract[20]	new[20]	_	_
7-3	353-356	fat	abstract[20]|substance|abstract[22]	new[20]|new|new[22]	coref	7-47
7-4	357-361	mass	abstract[20]|abstract[22]	new[20]|new[22]	_	_
7-5	362-365	≥28	abstract[20]|quantity[23]	new[20]|new[23]	_	_
7-6	366-367	%	abstract[20]|quantity[23]	new[20]|new[23]	_	_
7-7	368-370	in	abstract[20]|quantity[23]	new[20]|new[23]	_	_
7-8	371-374	men	abstract[20]|quantity[23]|person	new[20]|new[23]|new	coref	7-21
7-9	375-378	and	abstract[20]	new[20]	_	_
7-10	379-382	≥40	abstract[20]|quantity[25]	new[20]|new[25]	coref	24-42[200_25]
7-11	383-384	%	abstract[20]|quantity[25]	new[20]|new[25]	_	_
7-12	385-387	in	abstract[20]|quantity[25]	new[20]|new[25]	_	_
7-13	388-393	women	abstract[20]|quantity[25]|person	new[20]|new[25]|new	coref	7-26
7-14	394-395	;	_	_	_	_
7-15	396-397	-	_	_	_	_
7-16	398-403	Waist	object|place[28]	new|new[28]	coref|coref	7-32|7-31[35_28]
7-17	404-417	circumference	place[28]	new[28]	_	_
7-18	418-422	˃102	quantity[29]	new[29]	_	_
7-19	423-425	cm	quantity[29]	new[29]	_	_
7-20	426-428	in	quantity[29]	new[29]	_	_
7-21	429-432	men	quantity[29]|person	new[29]|giv	coref	7-37
7-22	433-436	and	_	_	_	_
7-23	437-440	˃88	quantity[31]	new[31]	coref	7-34[36_31]
7-24	441-443	cm	quantity[31]	new[31]	_	_
7-25	444-446	in	quantity[31]	new[31]	_	_
7-26	447-452	women	quantity[31]|person	new[31]|giv	appos	7-28[33_0]
7-27	453-454	(	_	_	_	_
7-28	455-460	Asian	person[33]	giv[33]	coref	7-42[0_33]
7-29	461-471	population	person[33]	giv[33]	_	_
7-30	472-473	:	_	_	_	_
7-31	474-475	A	place[35]	giv[35]	coref	16-6[117_35]
7-32	476-481	waist	object|place[35]	giv|giv[35]	coref	16-6
7-33	482-495	circumference	place[35]	giv[35]	_	_
7-34	496-499	˃90	place[35]|quantity[36]	giv[35]|giv[36]	coref	7-39[38_36]
7-35	500-502	cm	place[35]|quantity[36]	giv[35]|giv[36]	_	_
7-36	503-505	in	place[35]|quantity[36]	giv[35]|giv[36]	_	_
7-37	506-509	men	place[35]|quantity[36]|person	giv[35]|giv[36]|giv	_	_
7-38	510-513	and	_	_	_	_
7-39	514-517	˃80	quantity[38]	giv[38]	_	_
7-40	518-520	cm	quantity[38]	giv[38]	_	_
7-41	521-523	in	quantity[38]	giv[38]	_	_
7-42	524-529	women	quantity[38]|person	giv[38]|giv	_	_
7-43	530-531	)	_	_	_	_
7-44	532-533	;	_	_	_	_
7-45	534-535	-	_	_	_	_
7-46	536-544	Visceral	abstract[41]	new[41]	coref	19-14[158_41]
7-47	545-548	fat	substance|abstract[41]	giv|new[41]	coref	13-1[92_0]
7-48	549-553	area	abstract[41]	new[41]	_	_
7-49	554-558	≥100	quantity[42]	new[42]	_	_
7-50	559-562	cm2	quantity[42]	new[42]	_	_
7-51	563-565	on	quantity[42]	new[42]	_	_
7-52	566-575	abdominal	quantity[42]|person	new[42]|new	_	_
7-53	576-584	computed	_	_	_	_
7-54	585-595	tomography	object	new	_	_
7-55	596-597	.	_	_	_	_

#Text=The use of BMI has several limitations in patients with decompensated cirrhosis , as reflected by the fact that sarcopenia outperforms BMI as a predictor of outcomes after LT .
8-1	598-601	The	abstract[45]	new[45]	coref	18-30[152_45]
8-2	602-605	use	abstract[45]	new[45]	_	_
8-3	606-608	of	abstract[45]	new[45]	_	_
8-4	609-612	BMI	abstract[45]|organization	new[45]|giv	coref	8-22
8-5	613-616	has	_	_	_	_
8-6	617-624	several	abstract[47]	new[47]	coref	17-6[122_47]
8-7	625-636	limitations	abstract[47]	new[47]	_	_
8-8	637-639	in	abstract[47]	new[47]	_	_
8-9	640-648	patients	abstract[47]|person[48]	new[47]|giv[48]	coref	9-46[0_48]
8-10	649-653	with	abstract[47]|person[48]	new[47]|giv[48]	_	_
8-11	654-667	decompensated	abstract[47]|person[48]|abstract[49]	new[47]|giv[48]|giv[49]	coref	12-33[91_49]
8-12	668-677	cirrhosis	abstract[47]|person[48]|abstract[49]	new[47]|giv[48]|giv[49]	_	_
8-13	678-679	,	_	_	_	_
8-14	680-682	as	_	_	_	_
8-15	683-692	reflected	_	_	_	_
8-16	693-695	by	_	_	_	_
8-17	696-699	the	abstract[50]	new[50]	coref	15-3[107_50]
8-18	700-704	fact	abstract[50]	new[50]	_	_
8-19	705-709	that	abstract[50]	new[50]	_	_
8-20	710-720	sarcopenia	abstract[50]|abstract	new[50]|new	coref	12-12
8-21	721-732	outperforms	abstract[50]	new[50]	_	_
8-22	733-736	BMI	abstract[50]|organization	new[50]|giv	coref	9-5[55_0]
8-23	737-739	as	_	_	_	_
8-24	740-741	a	_	_	_	_
8-25	742-751	predictor	_	_	_	_
8-26	752-754	of	_	_	_	_
8-27	755-763	outcomes	abstract	new	coref	17-72[141_0]
8-28	764-769	after	_	_	_	_
8-29	770-772	LT	event	giv	coref	9-40
8-30	773-774	.	_	_	_	_

#Text=First of all , a high BMI may be due to fluid overload/ascites , and not obesity per se , as exemplified in a study in which adjusting BMI for the liters of ascites drained at the time of LT resulted in moving one-fifth of patients from one BMI category to a lower one .
9-1	775-780	First	_	_	_	_
9-2	781-783	of	_	_	_	_
9-3	784-787	all	_	_	_	_
9-4	788-789	,	_	_	_	_
9-5	790-791	a	organization[55]	giv[55]	coref	9-29[0_55]
9-6	792-796	high	organization[55]	giv[55]	_	_
9-7	797-800	BMI	organization[55]	giv[55]	_	_
9-8	801-804	may	_	_	_	_
9-9	805-807	be	_	_	_	_
9-10	808-811	due	_	_	_	_
9-11	812-814	to	_	_	_	_
9-12	815-820	fluid	substance|abstract[57]	new|new[57]	coref	17-35
9-13	821-837	overload/ascites	abstract[57]	new[57]	_	_
9-14	838-839	,	_	_	_	_
9-15	840-843	and	_	_	_	_
9-16	844-847	not	_	_	_	_
9-17	848-855	obesity	abstract[58]	giv[58]	coref	16-15[119_58]
9-18	856-859	per	abstract[58]	giv[58]	_	_
9-19	860-862	se	abstract[58]|abstract	giv[58]|new	_	_
9-20	863-864	,	_	_	_	_
9-21	865-867	as	_	_	_	_
9-22	868-879	exemplified	_	_	_	_
9-23	880-882	in	_	_	_	_
9-24	883-884	a	event[60]	new[60]	_	_
9-25	885-890	study	event[60]	new[60]	_	_
9-26	891-893	in	_	_	_	_
9-27	894-899	which	_	_	_	_
9-28	900-909	adjusting	_	_	_	_
9-29	910-913	BMI	organization	giv	coref	9-49
9-30	914-917	for	_	_	_	_
9-31	918-921	the	quantity[62]	new[62]	_	_
9-32	922-928	liters	quantity[62]	new[62]	_	_
9-33	929-931	of	quantity[62]	new[62]	_	_
9-34	932-939	ascites	quantity[62]|abstract	new[62]|new	coref	17-53
9-35	940-947	drained	_	_	_	_
9-36	948-950	at	_	_	_	_
9-37	951-954	the	_	_	_	_
9-38	955-959	time	_	_	_	_
9-39	960-962	of	_	_	_	_
9-40	963-965	LT	event	giv	coref	17-68
9-41	966-974	resulted	_	_	_	_
9-42	975-977	in	_	_	_	_
9-43	978-984	moving	_	_	_	_
9-44	985-994	one-fifth	abstract[65]	new[65]	_	_
9-45	995-997	of	abstract[65]	new[65]	_	_
9-46	998-1006	patients	abstract[65]|person	new[65]|giv	coref	12-28[90_0]
9-47	1007-1011	from	_	_	_	_
9-48	1012-1015	one	abstract[68]	new[68]	_	_
9-49	1016-1019	BMI	organization|abstract[68]	giv|new[68]	coref	10-3
9-50	1020-1028	category	abstract[68]	new[68]	_	_
9-51	1029-1031	to	abstract[68]	new[68]	_	_
9-52	1032-1033	a	abstract[68]|abstract[69]	new[68]|new[69]	coref	12-14[87_69]
9-53	1034-1039	lower	abstract[68]|abstract[69]	new[68]|new[69]	_	_
9-54	1040-1043	one	abstract[68]|abstract[69]	new[68]|new[69]	_	_
9-55	1044-1045	.	_	_	_	_

#Text=Also , BMI gives no information about body composition :
10-1	1046-1050	Also	_	_	_	_
10-2	1051-1052	,	_	_	_	_
10-3	1053-1056	BMI	organization	giv	coref	12-21
10-4	1057-1062	gives	_	_	_	_
10-5	1063-1065	no	abstract[71]	new[71]	_	_
10-6	1066-1077	information	abstract[71]	new[71]	_	_
10-7	1078-1083	about	abstract[71]	new[71]	_	_
10-8	1084-1088	body	abstract[71]|object|abstract[73]	new[71]|new|new[73]	ana|coref	11-1[0_73]|12-4
10-9	1089-1100	composition	abstract[71]|abstract[73]	new[71]|new[73]	_	_
10-10	1101-1102	:	_	_	_	_

#Text=It cannot tell the difference between muscle , subcutaneous , or visceral adipose tissue , which have different implications .
11-1	1103-1105	It	abstract	giv	coref	12-4[82_0]
11-2	1106-1112	cannot	_	_	_	_
11-3	1113-1117	tell	_	_	_	_
11-4	1118-1121	the	abstract[75]	new[75]	_	_
11-5	1122-1132	difference	abstract[75]	new[75]	_	_
11-6	1133-1140	between	abstract[75]	new[75]	_	_
11-7	1141-1147	muscle	abstract[75]|object	new[75]|new	_	_
11-8	1148-1149	,	abstract[75]	new[75]	_	_
11-9	1150-1162	subcutaneous	abstract[75]	new[75]	_	_
11-10	1163-1164	,	abstract[75]	new[75]	_	_
11-11	1165-1167	or	abstract[75]	new[75]	_	_
11-12	1168-1176	visceral	abstract[75]|object[78]	new[75]|new[78]	_	_
11-13	1177-1184	adipose	abstract[75]|abstract|object[78]	new[75]|new|new[78]	coref	12-16
11-14	1185-1191	tissue	abstract[75]|object[78]	new[75]|new[78]	_	_
11-15	1192-1193	,	_	_	_	_
11-16	1194-1199	which	_	_	_	_
11-17	1200-1204	have	_	_	_	_
11-18	1205-1214	different	abstract[79]	new[79]	_	_
11-19	1215-1227	implications	abstract[79]	new[79]	_	_
11-20	1228-1229	.	_	_	_	_

#Text=Studies looking at body composition on cross-sectional imaging have found that sarcopenia and low subcutaneous adipose tissue , but not BMI , are associated with mortality in male and female patients with cirrhosis , respectively .
12-1	1230-1237	Studies	abstract	new	_	_
12-2	1238-1245	looking	_	_	_	_
12-3	1246-1248	at	_	_	_	_
12-4	1249-1253	body	object|abstract[82]	giv|giv[82]	coref	19-19
12-5	1254-1265	composition	abstract[82]	giv[82]	_	_
12-6	1266-1268	on	abstract[82]	giv[82]	_	_
12-7	1269-1284	cross-sectional	abstract[82]|object[83]	giv[82]|new[83]	_	_
12-8	1285-1292	imaging	abstract[82]|object[83]	giv[82]|new[83]	_	_
12-9	1293-1297	have	_	_	_	_
12-10	1298-1303	found	_	_	_	_
12-11	1304-1308	that	_	_	_	_
12-12	1309-1319	sarcopenia	abstract	giv	coref	13-7
12-13	1320-1323	and	_	_	_	_
12-14	1324-1327	low	object[87]	giv[87]	coref	14-25[104_87]
12-15	1328-1340	subcutaneous	abstract|object[87]	new|giv[87]	coref	19-49
12-16	1341-1348	adipose	abstract|object[87]	giv|giv[87]	coref	19-50
12-17	1349-1355	tissue	object[87]	giv[87]	_	_
12-18	1356-1357	,	_	_	_	_
12-19	1358-1361	but	_	_	_	_
12-20	1362-1365	not	_	_	_	_
12-21	1366-1369	BMI	organization	giv	coref	15-17[111_0]
12-22	1370-1371	,	_	_	_	_
12-23	1372-1375	are	_	_	_	_
12-24	1376-1386	associated	_	_	_	_
12-25	1387-1391	with	_	_	_	_
12-26	1392-1401	mortality	abstract[89]	new[89]	coref	13-20[95_89]
12-27	1402-1404	in	abstract[89]	new[89]	_	_
12-28	1405-1409	male	abstract[89]|person[90]	new[89]|giv[90]	coref	14-12[100_90]
12-29	1410-1413	and	abstract[89]|person[90]	new[89]|giv[90]	_	_
12-30	1414-1420	female	abstract[89]|person[90]	new[89]|giv[90]	_	_
12-31	1421-1429	patients	abstract[89]|person[90]	new[89]|giv[90]	_	_
12-32	1430-1434	with	abstract[89]|person[90]	new[89]|giv[90]	_	_
12-33	1435-1444	cirrhosis	abstract[89]|person[90]|abstract[91]	new[89]|giv[90]|giv[91]	coref	17-24[0_91]
12-34	1445-1446	,	abstract[89]|person[90]|abstract[91]	new[89]|giv[90]|giv[91]	_	_
12-35	1447-1459	respectively	abstract[89]|person[90]|abstract[91]	new[89]|giv[90]|giv[91]	_	_
12-36	1460-1461	.	_	_	_	_

#Text=Excessive visceral fat when associated with sarcopenia , a term known as sarcopenic obesity , is also associated with increased mortality .
13-1	1462-1471	Excessive	substance[92]	giv[92]	coref	19-16[0_92]
13-2	1472-1480	visceral	substance[92]	giv[92]	_	_
13-3	1481-1484	fat	substance[92]	giv[92]	_	_
13-4	1485-1489	when	_	_	_	_
13-5	1490-1500	associated	_	_	_	_
13-6	1501-1505	with	_	_	_	_
13-7	1506-1516	sarcopenia	abstract	giv	appos	13-9[94_0]
13-8	1517-1518	,	_	_	_	_
13-9	1519-1520	a	abstract[94]	giv[94]	coref	14-14[0_94]
13-10	1521-1525	term	abstract[94]	giv[94]	_	_
13-11	1526-1531	known	_	_	_	_
13-12	1532-1534	as	_	_	_	_
13-13	1535-1545	sarcopenic	_	_	_	_
13-14	1546-1553	obesity	_	_	_	_
13-15	1554-1555	,	_	_	_	_
13-16	1556-1558	is	_	_	_	_
13-17	1559-1563	also	_	_	_	_
13-18	1564-1574	associated	_	_	_	_
13-19	1575-1579	with	_	_	_	_
13-20	1580-1589	increased	abstract[95]	giv[95]	coref	14-37[0_95]
13-21	1590-1599	mortality	abstract[95]	giv[95]	_	_
13-22	1600-1601	.	_	_	_	_

#Text=In the case of living donor liver transplant ( LDLT ) patients , sarcopenia , myosteatosis , and the visceral-to-subcutaneous-adipose-tissue ratio , but not visceral or subcutaneous tissue on their own , have been associated with mortality .
14-1	1602-1604	In	_	_	_	_
14-2	1605-1608	the	abstract[96]	new[96]	_	_
14-3	1609-1613	case	abstract[96]	new[96]	_	_
14-4	1614-1616	of	_	_	_	_
14-5	1617-1623	living	_	_	_	_
14-6	1624-1629	donor	person[98]	new[98]	_	_
14-7	1630-1635	liver	object|person[98]	giv|new[98]	coref	17-17
14-8	1636-1646	transplant	person[98]	new[98]	_	_
14-9	1647-1648	(	_	_	_	_
14-10	1649-1653	LDLT	abstract	new	_	_
14-11	1654-1655	)	_	_	_	_
14-12	1656-1664	patients	person[100]	giv[100]	coref	16-17[120_100]
14-13	1665-1666	,	person[100]	giv[100]	_	_
14-14	1667-1677	sarcopenia	person[100]|abstract	giv[100]|giv	coref	19-43
14-15	1678-1679	,	person[100]	giv[100]	_	_
14-16	1680-1692	myosteatosis	person[100]|abstract	giv[100]|new	_	_
14-17	1693-1694	,	person[100]	giv[100]	_	_
14-18	1695-1698	and	person[100]	giv[100]	_	_
14-19	1699-1702	the	person[100]|quantity[103]	giv[100]|new[103]	_	_
14-20	1703-1742	visceral-to-subcutaneous-adipose-tissue	person[100]|quantity[103]	giv[100]|new[103]	_	_
14-21	1743-1748	ratio	person[100]|quantity[103]	giv[100]|new[103]	_	_
14-22	1749-1750	,	person[100]	giv[100]	_	_
14-23	1751-1754	but	person[100]	giv[100]	_	_
14-24	1755-1758	not	person[100]	giv[100]	_	_
14-25	1759-1767	visceral	person[100]|object[104]	giv[100]|giv[104]	coref	19-48[171_104]
14-26	1768-1770	or	person[100]|object[104]	giv[100]|giv[104]	_	_
14-27	1771-1783	subcutaneous	person[100]|object[104]	giv[100]|giv[104]	_	_
14-28	1784-1790	tissue	person[100]|object[104]	giv[100]|giv[104]	_	_
14-29	1791-1793	on	person[100]|object[104]	giv[100]|giv[104]	_	_
14-30	1794-1799	their	person[100]|object[104]	giv[100]|giv[104]	_	_
14-31	1800-1803	own	person[100]|object[104]	giv[100]|giv[104]	_	_
14-32	1804-1805	,	_	_	_	_
14-33	1806-1810	have	_	_	_	_
14-34	1811-1815	been	_	_	_	_
14-35	1816-1826	associated	_	_	_	_
14-36	1827-1831	with	_	_	_	_
14-37	1832-1841	mortality	abstract	giv	ana	15-1
14-38	1842-1843	.	_	_	_	_

#Text=This reinforces the fact that more than the size of a patient , which is what the BMI stands for , it is the composition that matters .
15-1	1844-1848	This	abstract	giv	ana	15-5
15-2	1849-1859	reinforces	_	_	_	_
15-3	1860-1863	the	abstract[107]	giv[107]	_	_
15-4	1864-1868	fact	abstract[107]	giv[107]	_	_
15-5	1869-1873	that	abstract	giv	ana	15-22
15-6	1874-1878	more	quantity[109]	new[109]	_	_
15-7	1879-1883	than	quantity[109]	new[109]	_	_
15-8	1884-1887	the	quantity[109]	new[109]	_	_
15-9	1888-1892	size	quantity[109]	new[109]	_	_
15-10	1893-1895	of	quantity[109]	new[109]	_	_
15-11	1896-1897	a	quantity[109]|person[110]	new[109]|new[110]	coref	27-17[236_110]
15-12	1898-1905	patient	quantity[109]|person[110]	new[109]|new[110]	_	_
15-13	1906-1907	,	_	_	_	_
15-14	1908-1913	which	_	_	_	_
15-15	1914-1916	is	_	_	_	_
15-16	1917-1921	what	_	_	_	_
15-17	1922-1925	the	organization[111]	giv[111]	coref	17-28[130_111]
15-18	1926-1929	BMI	organization[111]	giv[111]	_	_
15-19	1930-1936	stands	_	_	_	_
15-20	1937-1940	for	_	_	_	_
15-21	1941-1942	,	_	_	_	_
15-22	1943-1945	it	abstract	giv	coref	15-24[113_0]
15-23	1946-1948	is	_	_	_	_
15-24	1949-1952	the	abstract[113]	giv[113]	coref	19-20[0_113]
15-25	1953-1964	composition	abstract[113]	giv[113]	_	_
15-26	1965-1969	that	_	_	_	_
15-27	1970-1977	matters	event	new	_	_
15-28	1978-1979	.	_	_	_	_

#Text=For the same reasons , waist circumference is not the best method to assess obesity in these patients .
16-1	1980-1983	For	_	_	_	_
16-2	1984-1987	the	abstract[115]	new[115]	ana	17-4[121_115]
16-3	1988-1992	same	abstract[115]	new[115]	_	_
16-4	1993-2000	reasons	abstract[115]	new[115]	_	_
16-5	2001-2002	,	_	_	_	_
16-6	2003-2008	waist	object|place[117]	giv|giv[117]	_	_
16-7	2009-2022	circumference	place[117]	giv[117]	_	_
16-8	2023-2025	is	_	_	_	_
16-9	2026-2029	not	_	_	_	_
16-10	2030-2033	the	abstract[118]	new[118]	_	_
16-11	2034-2038	best	abstract[118]	new[118]	_	_
16-12	2039-2045	method	abstract[118]	new[118]	_	_
16-13	2046-2048	to	_	_	_	_
16-14	2049-2055	assess	_	_	_	_
16-15	2056-2063	obesity	abstract[119]	giv[119]	coref	19-9[0_119]
16-16	2064-2066	in	abstract[119]	giv[119]	_	_
16-17	2067-2072	these	abstract[119]|person[120]	giv[119]|giv[120]	coref	17-22[128_120]
16-18	2073-2081	patients	abstract[119]|person[120]	giv[119]|giv[120]	_	_
16-19	2082-2083	.	_	_	_	_

#Text=Trying to circumvent some of these limitations , the European Association for the Study of the Liver guidelines for nutrition in patients with cirrhosis recommend to adjust the BMI for the confounding effect of fluid retention ( i. e. , dry-BMI ) , though there is no perfect correlation between BMI and ascites , and in fact , BMI corrected for ascites drained at the time of LT failed to predict relevant outcomes after LT .
17-1	2084-2090	Trying	_	_	_	_
17-2	2091-2093	to	_	_	_	_
17-3	2094-2104	circumvent	_	_	_	_
17-4	2105-2109	some	abstract[121]	giv[121]	_	_
17-5	2110-2112	of	abstract[121]	giv[121]	_	_
17-6	2113-2118	these	abstract[121]|abstract[122]	giv[121]|giv[122]	_	_
17-7	2119-2130	limitations	abstract[121]|abstract[122]	giv[121]|giv[122]	_	_
17-8	2131-2132	,	_	_	_	_
17-9	2133-2136	the	organization[123]	new[123]	coref	22-18[181_123]
17-10	2137-2145	European	organization[123]	new[123]	_	_
17-11	2146-2157	Association	organization[123]	new[123]	_	_
17-12	2158-2161	for	organization[123]	new[123]	_	_
17-13	2162-2165	the	organization[123]|abstract[124]	new[123]|new[124]	_	_
17-14	2166-2171	Study	organization[123]|abstract[124]	new[123]|new[124]	_	_
17-15	2172-2174	of	organization[123]|abstract[124]	new[123]|new[124]	_	_
17-16	2175-2178	the	organization[123]|abstract[124]|abstract[126]	new[123]|new[124]|new[126]	_	_
17-17	2179-2184	Liver	organization[123]|abstract[124]|object|abstract[126]	new[123]|new[124]|giv|new[126]	coref	22-25[183_0]
17-18	2185-2195	guidelines	organization[123]|abstract[124]|abstract[126]	new[123]|new[124]|new[126]	_	_
17-19	2196-2199	for	organization[123]|abstract[124]|abstract[126]	new[123]|new[124]|new[126]	_	_
17-20	2200-2209	nutrition	organization[123]|abstract[124]|abstract[126]|abstract	new[123]|new[124]|new[126]|new	_	_
17-21	2210-2212	in	organization[123]|abstract[124]|abstract[126]	new[123]|new[124]|new[126]	_	_
17-22	2213-2221	patients	organization[123]|abstract[124]|abstract[126]|person[128]	new[123]|new[124]|new[126]|giv[128]	coref	21-2[173_128]
17-23	2222-2226	with	organization[123]|abstract[124]|abstract[126]|person[128]	new[123]|new[124]|new[126]|giv[128]	_	_
17-24	2227-2236	cirrhosis	organization[123]|abstract[124]|abstract[126]|person[128]|abstract	new[123]|new[124]|new[126]|giv[128]|giv	_	_
17-25	2237-2246	recommend	_	_	_	_
17-26	2247-2249	to	_	_	_	_
17-27	2250-2256	adjust	_	_	_	_
17-28	2257-2260	the	organization[130]	giv[130]	coref	17-51[0_130]
17-29	2261-2264	BMI	organization[130]	giv[130]	_	_
17-30	2265-2268	for	organization[130]	giv[130]	_	_
17-31	2269-2272	the	organization[130]|abstract[131]	giv[130]|new[131]	_	_
17-32	2273-2284	confounding	organization[130]|abstract[131]	giv[130]|new[131]	_	_
17-33	2285-2291	effect	organization[130]|abstract[131]	giv[130]|new[131]	_	_
17-34	2292-2294	of	organization[130]|abstract[131]	giv[130]|new[131]	_	_
17-35	2295-2300	fluid	organization[130]|abstract[131]|substance|abstract[133]	giv[130]|new[131]|giv|new[133]	_	_
17-36	2301-2310	retention	organization[130]|abstract[131]|abstract[133]	giv[130]|new[131]|new[133]	_	_
17-37	2311-2312	(	_	_	_	_
17-38	2313-2315	i.	_	_	_	_
17-39	2316-2318	e.	_	_	_	_
17-40	2319-2320	,	_	_	_	_
17-41	2321-2328	dry-BMI	abstract	new	_	_
17-42	2329-2330	)	_	_	_	_
17-43	2331-2332	,	_	_	_	_
17-44	2333-2339	though	_	_	_	_
17-45	2340-2345	there	_	_	_	_
17-46	2346-2348	is	_	_	_	_
17-47	2349-2351	no	abstract[135]	new[135]	_	_
17-48	2352-2359	perfect	abstract[135]	new[135]	_	_
17-49	2360-2371	correlation	abstract[135]	new[135]	_	_
17-50	2372-2379	between	abstract[135]	new[135]	_	_
17-51	2380-2383	BMI	abstract[135]|abstract	new[135]|giv	coref	17-59
17-52	2384-2387	and	abstract[135]	new[135]	_	_
17-53	2388-2395	ascites	abstract[135]|abstract	new[135]|giv	coref	17-62
17-54	2396-2397	,	abstract[135]	new[135]	_	_
17-55	2398-2401	and	abstract[135]	new[135]	_	_
17-56	2402-2404	in	abstract[135]	new[135]	_	_
17-57	2405-2409	fact	abstract[135]	new[135]	_	_
17-58	2410-2411	,	abstract[135]	new[135]	_	_
17-59	2412-2415	BMI	abstract[135]|abstract	new[135]|giv	coref	18-3[143_0]
17-60	2416-2425	corrected	_	_	_	_
17-61	2426-2429	for	_	_	_	_
17-62	2430-2437	ascites	abstract	giv	_	_
17-63	2438-2445	drained	_	_	_	_
17-64	2446-2448	at	_	_	_	_
17-65	2449-2452	the	_	_	_	_
17-66	2453-2457	time	_	_	_	_
17-67	2458-2460	of	_	_	_	_
17-68	2461-2463	LT	event	giv	coref	17-75
17-69	2464-2470	failed	_	_	_	_
17-70	2471-2473	to	_	_	_	_
17-71	2474-2481	predict	_	_	_	_
17-72	2482-2490	relevant	abstract[141]	giv[141]	coref	18-34[153_141]
17-73	2491-2499	outcomes	abstract[141]	giv[141]	_	_
17-74	2500-2505	after	_	_	_	_
17-75	2506-2508	LT	event	giv	coref	19-35
17-76	2509-2510	.	_	_	_	_

#Text=Likewise , a modified BMI calculated by multiplying BMI ( kg/m2 ) by serum albumin ( g/L ) with the intention of compensating for volume overload was found of no use to predict clinical outcomes .
18-1	2511-2519	Likewise	_	_	_	_
18-2	2520-2521	,	_	_	_	_
18-3	2522-2523	a	organization[143]	giv[143]	coref	18-9[0_143]
18-4	2524-2532	modified	organization[143]	giv[143]	_	_
18-5	2533-2536	BMI	organization[143]	giv[143]	_	_
18-6	2537-2547	calculated	_	_	_	_
18-7	2548-2550	by	_	_	_	_
18-8	2551-2562	multiplying	_	_	_	_
18-9	2563-2566	BMI	abstract	giv	coref	25-10
18-10	2567-2568	(	_	_	_	_
18-11	2569-2574	kg/m2	quantity	giv	_	_
18-12	2575-2576	)	_	_	_	_
18-13	2577-2579	by	_	_	_	_
18-14	2580-2585	serum	abstract|substance[147]	new|new[147]	_	_
18-15	2586-2593	albumin	substance[147]	new[147]	_	_
18-16	2594-2595	(	_	_	_	_
18-17	2596-2599	g/L	quantity	new	_	_
18-18	2600-2601	)	_	_	_	_
18-19	2602-2606	with	_	_	_	_
18-20	2607-2610	the	abstract[149]	new[149]	_	_
18-21	2611-2620	intention	abstract[149]	new[149]	_	_
18-22	2621-2623	of	_	_	_	_
18-23	2624-2636	compensating	_	_	_	_
18-24	2637-2640	for	_	_	_	_
18-25	2641-2647	volume	abstract|abstract[151]	new|new[151]	_	_
18-26	2648-2656	overload	abstract[151]	new[151]	_	_
18-27	2657-2660	was	_	_	_	_
18-28	2661-2666	found	_	_	_	_
18-29	2667-2669	of	_	_	_	_
18-30	2670-2672	no	abstract[152]	giv[152]	_	_
18-31	2673-2676	use	abstract[152]	giv[152]	_	_
18-32	2677-2679	to	_	_	_	_
18-33	2680-2687	predict	_	_	_	_
18-34	2688-2696	clinical	abstract[153]	giv[153]	coref	23-10[0_153]
18-35	2697-2705	outcomes	abstract[153]	giv[153]	_	_
18-36	2706-2707	.	_	_	_	_

#Text=In conclusion , when available , we suggest obesity be defined according to the visceral fat area on body composition analysis , especially in the research setting , because the impact of obesity on LT may be modified by the coexistence of sarcopenia , myosteatosis , and/or low subcutaneous adipose tissue .
19-1	2708-2710	In	_	_	_	_
19-2	2711-2721	conclusion	abstract	new	_	_
19-3	2722-2723	,	_	_	_	_
19-4	2724-2728	when	_	_	_	_
19-5	2729-2738	available	_	_	_	_
19-6	2739-2740	,	_	_	_	_
19-7	2741-2743	we	person	acc	_	_
19-8	2744-2751	suggest	_	_	_	_
19-9	2752-2759	obesity	abstract	giv	coref	19-33
19-10	2760-2762	be	_	_	_	_
19-11	2763-2770	defined	_	_	_	_
19-12	2771-2780	according	_	_	_	_
19-13	2781-2783	to	_	_	_	_
19-14	2784-2787	the	abstract[158]	giv[158]	_	_
19-15	2788-2796	visceral	abstract[158]	giv[158]	_	_
19-16	2797-2800	fat	substance|abstract[158]	giv|giv[158]	_	_
19-17	2801-2805	area	abstract[158]	giv[158]	_	_
19-18	2806-2808	on	abstract[158]	giv[158]	_	_
19-19	2809-2813	body	abstract[158]|object|abstract[161]	giv[158]|giv|new[161]	_	_
19-20	2814-2825	composition	abstract[158]|abstract|abstract[161]	giv[158]|giv|new[161]	_	_
19-21	2826-2834	analysis	abstract[158]|abstract[161]	giv[158]|new[161]	_	_
19-22	2835-2836	,	abstract[158]|abstract[161]	giv[158]|new[161]	_	_
19-23	2837-2847	especially	abstract[158]|abstract[161]|abstract[163]	giv[158]|new[161]|new[163]	_	_
19-24	2848-2850	in	abstract[158]|abstract[161]|abstract[163]	giv[158]|new[161]|new[163]	_	_
19-25	2851-2854	the	abstract[158]|abstract[161]|abstract[163]	giv[158]|new[161]|new[163]	_	_
19-26	2855-2863	research	abstract[158]|abstract[161]|abstract|abstract[163]	giv[158]|new[161]|new|new[163]	_	_
19-27	2864-2871	setting	abstract[158]|abstract[161]|abstract[163]	giv[158]|new[161]|new[163]	_	_
19-28	2872-2873	,	_	_	_	_
19-29	2874-2881	because	_	_	_	_
19-30	2882-2885	the	abstract[164]	new[164]	_	_
19-31	2886-2892	impact	abstract[164]	new[164]	_	_
19-32	2893-2895	of	abstract[164]	new[164]	_	_
19-33	2896-2903	obesity	abstract[164]|abstract	new[164]|giv	coref	22-5[177_0]
19-34	2904-2906	on	abstract[164]	new[164]	_	_
19-35	2907-2909	LT	abstract[164]|abstract	new[164]|giv	coref	21-8
19-36	2910-2913	may	_	_	_	_
19-37	2914-2916	be	_	_	_	_
19-38	2917-2925	modified	_	_	_	_
19-39	2926-2928	by	_	_	_	_
19-40	2929-2932	the	abstract[167]	new[167]	_	_
19-41	2933-2944	coexistence	abstract[167]	new[167]	_	_
19-42	2945-2947	of	abstract[167]	new[167]	_	_
19-43	2948-2958	sarcopenia	abstract[167]|abstract	new[167]|giv	_	_
19-44	2959-2960	,	abstract[167]	new[167]	_	_
19-45	2961-2973	myosteatosis	abstract[167]	new[167]	_	_
19-46	2974-2975	,	abstract[167]	new[167]	_	_
19-47	2976-2982	and/or	abstract[167]	new[167]	_	_
19-48	2983-2986	low	abstract[167]|object[171]	new[167]|giv[171]	_	_
19-49	2987-2999	subcutaneous	abstract[167]|abstract|object[171]	new[167]|giv|giv[171]	_	_
19-50	3000-3007	adipose	abstract[167]|abstract|object[171]	new[167]|giv|giv[171]	_	_
19-51	3008-3014	tissue	abstract[167]|object[171]	new[167]|giv[171]	_	_
19-52	3015-3016	.	_	_	_	_

#Text=2.2 .
20-1	3017-3020	2.2	abstract	new	_	_
20-2	3021-3022	.	_	_	_	_

#Text=Should Morbidly Obese Patients be Listed for LT ?
21-1	3023-3029	Should	_	_	_	_
21-2	3030-3038	Morbidly	person[173]	giv[173]	coref	24-4[189_173]
21-3	3039-3044	Obese	person[173]	giv[173]	_	_
21-4	3045-3053	Patients	person[173]	giv[173]	_	_
21-5	3054-3056	be	_	_	_	_
21-6	3057-3063	Listed	_	_	_	_
21-7	3064-3067	for	_	_	_	_
21-8	3068-3070	LT	abstract	giv	coref	22-2
21-9	3071-3072	?	_	_	_	_

#Text=Some LT programs consider morbid obesity a relative contraindication for LT based on the latest recommendations from the American Association for the Study of the Liver .
22-1	3073-3077	Some	abstract[176]	new[176]	_	_
22-2	3078-3080	LT	abstract|abstract[176]	giv|new[176]	coref	22-11
22-3	3081-3089	programs	abstract[176]	new[176]	_	_
22-4	3090-3098	consider	_	_	_	_
22-5	3099-3105	morbid	abstract[177]	giv[177]	coref	23-8[0_177]
22-6	3106-3113	obesity	abstract[177]	giv[177]	_	_
22-7	3114-3115	a	abstract[178]	new[178]	coref	27-35[241_178]
22-8	3116-3124	relative	abstract[178]	new[178]	_	_
22-9	3125-3141	contraindication	abstract[178]	new[178]	_	_
22-10	3142-3145	for	abstract[178]	new[178]	_	_
22-11	3146-3148	LT	abstract[178]|abstract	new[178]|giv	coref	23-12
22-12	3149-3154	based	_	_	_	_
22-13	3155-3157	on	_	_	_	_
22-14	3158-3161	the	abstract[180]	new[180]	_	_
22-15	3162-3168	latest	abstract[180]	new[180]	_	_
22-16	3169-3184	recommendations	abstract[180]	new[180]	_	_
22-17	3185-3189	from	abstract[180]	new[180]	_	_
22-18	3190-3193	the	abstract[180]|organization[181]	new[180]|giv[181]	_	_
22-19	3194-3202	American	abstract[180]|organization[181]	new[180]|giv[181]	_	_
22-20	3203-3214	Association	abstract[180]|organization[181]	new[180]|giv[181]	_	_
22-21	3215-3218	for	abstract[180]|organization[181]	new[180]|giv[181]	_	_
22-22	3219-3222	the	abstract[180]|organization[181]|abstract[182]	new[180]|giv[181]|new[182]	_	_
22-23	3223-3228	Study	abstract[180]|organization[181]|abstract[182]	new[180]|giv[181]|new[182]	_	_
22-24	3229-3231	of	abstract[180]|organization[181]|abstract[182]	new[180]|giv[181]|new[182]	_	_
22-25	3232-3235	the	abstract[180]|organization[181]|abstract[182]|object[183]	new[180]|giv[181]|new[182]|giv[183]	coref	26-26[0_183]
22-26	3236-3241	Liver	abstract[180]|organization[181]|abstract[182]|object[183]	new[180]|giv[181]|new[182]|giv[183]	_	_
22-27	3242-3243	.	_	_	_	_

#Text=However , evidence evaluating the role of obesity on outcomes after LT is conflicting .
23-1	3244-3251	However	abstract[184]	new[184]	coref	25-1[0_184]
23-2	3252-3253	,	abstract[184]	new[184]	_	_
23-3	3254-3262	evidence	abstract[184]	new[184]	_	_
23-4	3263-3273	evaluating	_	_	_	_
23-5	3274-3277	the	abstract[185]	new[185]	_	_
23-6	3278-3282	role	abstract[185]	new[185]	_	_
23-7	3283-3285	of	abstract[185]	new[185]	_	_
23-8	3286-3293	obesity	abstract[185]|abstract	new[185]|giv	coref	24-6[190_0]
23-9	3294-3296	on	_	_	_	_
23-10	3297-3305	outcomes	abstract	giv	coref	26-17[221_0]
23-11	3306-3311	after	_	_	_	_
23-12	3312-3314	LT	abstract	giv	coref	24-13
23-13	3315-3317	is	_	_	_	_
23-14	3318-3329	conflicting	_	_	_	_
23-15	3330-3331	.	_	_	_	_

#Text=When needed , patients with severe and morbid obesity do benefit from LT , meaning they live longer than they would do without it , and LT in these patients strays far away from being futile , with five-year survival rates well above 50 % .
24-1	3332-3336	When	_	_	_	_
24-2	3337-3343	needed	_	_	_	_
24-3	3344-3345	,	_	_	_	_
24-4	3346-3354	patients	person[189]	giv[189]	ana	24-16[0_189]
24-5	3355-3359	with	person[189]	giv[189]	_	_
24-6	3360-3366	severe	person[189]|abstract[190]	giv[189]|giv[190]	coref	25-20[0_190]
24-7	3367-3370	and	person[189]|abstract[190]	giv[189]|giv[190]	_	_
24-8	3371-3377	morbid	person[189]|abstract[190]	giv[189]|giv[190]	_	_
24-9	3378-3385	obesity	person[189]|abstract[190]	giv[189]|giv[190]	_	_
24-10	3386-3388	do	_	_	_	_
24-11	3389-3396	benefit	_	_	_	_
24-12	3397-3401	from	_	_	_	_
24-13	3402-3404	LT	abstract	giv	ana	24-24
24-14	3405-3406	,	_	_	_	_
24-15	3407-3414	meaning	_	_	_	_
24-16	3415-3419	they	person	giv	ana	24-20
24-17	3420-3424	live	_	_	_	_
24-18	3425-3431	longer	_	_	_	_
24-19	3432-3436	than	_	_	_	_
24-20	3437-3441	they	person	giv	coref	24-30
24-21	3442-3447	would	_	_	_	_
24-22	3448-3450	do	_	_	_	_
24-23	3451-3458	without	_	_	_	_
24-24	3459-3461	it	abstract	giv	coref	24-27[195_0]
24-25	3462-3463	,	_	_	_	_
24-26	3464-3467	and	_	_	_	_
24-27	3468-3470	LT	abstract[195]	giv[195]	coref	25-17[0_195]
24-28	3471-3473	in	abstract[195]	giv[195]	_	_
24-29	3474-3479	these	abstract[195]|object[197]	giv[195]|new[197]	_	_
24-30	3480-3488	patients	abstract[195]|person|object[197]	giv[195]|giv|new[197]	_	_
24-31	3489-3495	strays	abstract[195]|object[197]	giv[195]|new[197]	_	_
24-32	3496-3499	far	_	_	_	_
24-33	3500-3504	away	_	_	_	_
24-34	3505-3509	from	_	_	_	_
24-35	3510-3515	being	_	_	_	_
24-36	3516-3522	futile	_	_	_	_
24-37	3523-3524	,	_	_	_	_
24-38	3525-3529	with	_	_	_	_
24-39	3530-3539	five-year	abstract[199]	new[199]	_	_
24-40	3540-3548	survival	event|abstract[199]	new|new[199]	coref	26-33[226_0]
24-41	3549-3554	rates	abstract[199]	new[199]	_	_
24-42	3555-3559	well	abstract[199]|quantity[200]	new[199]|giv[200]	_	_
24-43	3560-3565	above	abstract[199]|quantity[200]	new[199]|giv[200]	_	_
24-44	3566-3568	50	abstract[199]|quantity[200]	new[199]|giv[200]	_	_
24-45	3569-3570	%	abstract[199]|quantity[200]	new[199]|giv[200]	_	_
24-46	3571-3572	.	_	_	_	_

#Text=Evidence so far does not support using a strict BMI cutoff to deny someone candidacy for LT , however obesity is frequently associated with other conditions that may be contraindications for LT such as cardiovascular disease , cancer , renal dysfunction , and pulmonary hypertension .
25-1	3573-3581	Evidence	abstract	giv	_	_
25-2	3582-3584	so	_	_	_	_
25-3	3585-3588	far	_	_	_	_
25-4	3589-3593	does	_	_	_	_
25-5	3594-3597	not	_	_	_	_
25-6	3598-3605	support	_	_	_	_
25-7	3606-3611	using	_	_	_	_
25-8	3612-3613	a	abstract[203]	new[203]	_	_
25-9	3614-3620	strict	abstract[203]	new[203]	_	_
25-10	3621-3624	BMI	organization|abstract[203]	giv|new[203]	_	_
25-11	3625-3631	cutoff	abstract[203]	new[203]	_	_
25-12	3632-3634	to	_	_	_	_
25-13	3635-3639	deny	_	_	_	_
25-14	3640-3647	someone	person|abstract[205]	new|new[205]	_	_
25-15	3648-3657	candidacy	abstract[205]	new[205]	_	_
25-16	3658-3661	for	abstract[205]	new[205]	_	_
25-17	3662-3664	LT	abstract[205]|abstract	new[205]|giv	coref	25-32[210_0]
25-18	3665-3666	,	_	_	_	_
25-19	3667-3674	however	_	_	_	_
25-20	3675-3682	obesity	abstract	giv	coref	26-3
25-21	3683-3685	is	_	_	_	_
25-22	3686-3696	frequently	_	_	_	_
25-23	3697-3707	associated	_	_	_	_
25-24	3708-3712	with	_	_	_	_
25-25	3713-3718	other	abstract[208]	new[208]	_	_
25-26	3719-3729	conditions	abstract[208]	new[208]	_	_
25-27	3730-3734	that	_	_	_	_
25-28	3735-3738	may	_	_	_	_
25-29	3739-3741	be	_	_	_	_
25-30	3742-3759	contraindications	abstract[209]	new[209]	_	_
25-31	3760-3763	for	abstract[209]	new[209]	_	_
25-32	3764-3766	LT	abstract[209]|abstract[210]	new[209]|giv[210]	coref	27-22[0_210]
25-33	3767-3771	such	abstract[209]|abstract[210]	new[209]|giv[210]	_	_
25-34	3772-3774	as	abstract[209]|abstract[210]	new[209]|giv[210]	_	_
25-35	3775-3789	cardiovascular	abstract[209]|abstract[210]|abstract[211]	new[209]|giv[210]|new[211]	coref	26-26[225_211]
25-36	3790-3797	disease	abstract[209]|abstract[210]|abstract[211]	new[209]|giv[210]|new[211]	_	_
25-37	3798-3799	,	abstract[209]|abstract[210]	new[209]|giv[210]	_	_
25-38	3800-3806	cancer	abstract[209]|abstract[210]|abstract	new[209]|giv[210]|new	_	_
25-39	3807-3808	,	abstract[209]|abstract[210]	new[209]|giv[210]	_	_
25-40	3809-3814	renal	abstract[209]|abstract[210]|abstract|abstract[214]	new[209]|giv[210]|new|new[214]	_	_
25-41	3815-3826	dysfunction	abstract[209]|abstract[210]|abstract[214]	new[209]|giv[210]|new[214]	_	_
25-42	3827-3828	,	abstract[209]|abstract[210]	new[209]|giv[210]	_	_
25-43	3829-3832	and	abstract[209]|abstract[210]	new[209]|giv[210]	_	_
25-44	3833-3842	pulmonary	abstract[209]|abstract[210]|person|abstract[216]	new[209]|giv[210]|new|new[216]	_	_
25-45	3843-3855	hypertension	abstract[209]|abstract[210]|abstract[216]	new[209]|giv[210]|new[216]	_	_
25-46	3856-3857	.	_	_	_	_

#Text=Also , obesity is a risk factor for NAFLD , which though traditionally considered to have similar post-LT outcomes to those of other etiologies of liver disease , may in fact have lower one-year survival due to cardiovascular and cerebrovascular diseases .
26-1	3858-3862	Also	_	_	_	_
26-2	3863-3864	,	_	_	_	_
26-3	3865-3872	obesity	abstract	giv	coref	26-5[219_0]
26-4	3873-3875	is	_	_	_	_
26-5	3876-3877	a	abstract[219]	giv[219]	coref	27-6[0_219]
26-6	3878-3882	risk	abstract|abstract[219]	new|giv[219]	_	_
26-7	3883-3889	factor	abstract[219]	giv[219]	_	_
26-8	3890-3893	for	abstract[219]	giv[219]	_	_
26-9	3894-3899	NAFLD	abstract[219]|abstract	giv[219]|new	ana	26-21[222_0]
26-10	3900-3901	,	_	_	_	_
26-11	3902-3907	which	_	_	_	_
26-12	3908-3914	though	_	_	_	_
26-13	3915-3928	traditionally	_	_	_	_
26-14	3929-3939	considered	_	_	_	_
26-15	3940-3942	to	_	_	_	_
26-16	3943-3947	have	_	_	_	_
26-17	3948-3955	similar	abstract[221]	giv[221]	coref	27-22[238_221]
26-18	3956-3963	post-LT	abstract[221]	giv[221]	_	_
26-19	3964-3972	outcomes	abstract[221]	giv[221]	_	_
26-20	3973-3975	to	_	_	_	_
26-21	3976-3981	those	abstract[222]	giv[222]	_	_
26-22	3982-3984	of	abstract[222]	giv[222]	_	_
26-23	3985-3990	other	abstract[222]|abstract[223]	giv[222]|new[223]	_	_
26-24	3991-4001	etiologies	abstract[222]|abstract[223]	giv[222]|new[223]	_	_
26-25	4002-4004	of	abstract[222]|abstract[223]	giv[222]|new[223]	_	_
26-26	4005-4010	liver	abstract[222]|abstract[223]|object|abstract[225]	giv[222]|new[223]|giv|giv[225]	_	_
26-27	4011-4018	disease	abstract[222]|abstract[223]|abstract[225]	giv[222]|new[223]|giv[225]	_	_
26-28	4019-4020	,	_	_	_	_
26-29	4021-4024	may	_	_	_	_
26-30	4025-4027	in	_	_	_	_
26-31	4028-4032	fact	_	_	_	_
26-32	4033-4037	have	_	_	_	_
26-33	4038-4043	lower	event[226]	giv[226]	_	_
26-34	4044-4052	one-year	event[226]	giv[226]	_	_
26-35	4053-4061	survival	event[226]	giv[226]	_	_
26-36	4062-4065	due	_	_	_	_
26-37	4066-4068	to	_	_	_	_
26-38	4069-4083	cardiovascular	abstract	new	_	_
26-39	4084-4087	and	_	_	_	_
26-40	4088-4103	cerebrovascular	abstract	new	_	_
26-41	4104-4112	diseases	abstract	new	_	_
26-42	4113-4114	.	_	_	_	_

#Text=In summary , more than obesity itself , it is the sum of the comorbidities of the individual patient that determines LT outcomes and as such , morbid obesity should not be considered on its own a contraindication for LT , but in turn should trigger a rigorous pre-LT assessment to carefully select potential recipients , as discussed below .
27-1	4115-4117	In	_	_	_	_
27-2	4118-4125	summary	abstract	new	ana	27-6[232_0]
27-3	4126-4127	,	_	_	_	_
27-4	4128-4132	more	_	_	_	_
27-5	4133-4137	than	_	_	_	_
27-6	4138-4145	obesity	abstract|abstract[232]	giv|giv[232]	ana|coref	27-9[0_232]|27-28[239_0]
27-7	4146-4152	itself	abstract[232]	giv[232]	_	_
27-8	4153-4154	,	_	_	_	_
27-9	4155-4157	it	quantity	giv	coref	27-11[234_0]
27-10	4158-4160	is	_	_	_	_
27-11	4161-4164	the	quantity[234]	giv[234]	ana	27-35[0_234]
27-12	4165-4168	sum	quantity[234]	giv[234]	_	_
27-13	4169-4171	of	quantity[234]	giv[234]	_	_
27-14	4172-4175	the	quantity[234]|abstract[235]	giv[234]|new[235]	_	_
27-15	4176-4189	comorbidities	quantity[234]|abstract[235]	giv[234]|new[235]	_	_
27-16	4190-4192	of	quantity[234]|abstract[235]	giv[234]|new[235]	_	_
27-17	4193-4196	the	quantity[234]|abstract[235]|person[236]	giv[234]|new[235]|giv[236]	_	_
27-18	4197-4207	individual	quantity[234]|abstract[235]|person[236]	giv[234]|new[235]|giv[236]	_	_
27-19	4208-4215	patient	quantity[234]|abstract[235]|person[236]	giv[234]|new[235]|giv[236]	_	_
27-20	4216-4220	that	_	_	_	_
27-21	4221-4231	determines	_	_	_	_
27-22	4232-4234	LT	abstract|abstract[238]	giv|giv[238]	coref	27-40
27-23	4235-4243	outcomes	abstract[238]	giv[238]	_	_
27-24	4244-4247	and	_	_	_	_
27-25	4248-4250	as	_	_	_	_
27-26	4251-4255	such	_	_	_	_
27-27	4256-4257	,	_	_	_	_
27-28	4258-4264	morbid	abstract[239]	giv[239]	_	_
27-29	4265-4272	obesity	abstract[239]	giv[239]	_	_
27-30	4273-4279	should	_	_	_	_
27-31	4280-4283	not	_	_	_	_
27-32	4284-4286	be	_	_	_	_
27-33	4287-4297	considered	_	_	_	_
27-34	4298-4300	on	_	_	_	_
27-35	4301-4304	its	abstract|abstract[241]	giv|giv[241]	_	_
27-36	4305-4308	own	abstract[241]	giv[241]	_	_
27-37	4309-4310	a	abstract[241]	giv[241]	_	_
27-38	4311-4327	contraindication	abstract[241]	giv[241]	_	_
27-39	4328-4331	for	abstract[241]	giv[241]	_	_
27-40	4332-4334	LT	abstract[241]|abstract	giv[241]|giv	_	_
27-41	4335-4336	,	_	_	_	_
27-42	4337-4340	but	_	_	_	_
27-43	4341-4343	in	_	_	_	_
27-44	4344-4348	turn	abstract	new	_	_
27-45	4349-4355	should	_	_	_	_
27-46	4356-4363	trigger	_	_	_	_
27-47	4364-4365	a	abstract[244]	new[244]	_	_
27-48	4366-4374	rigorous	abstract[244]	new[244]	_	_
27-49	4375-4381	pre-LT	abstract[244]	new[244]	_	_
27-50	4382-4392	assessment	abstract[244]	new[244]	_	_
27-51	4393-4395	to	_	_	_	_
27-52	4396-4405	carefully	_	_	_	_
27-53	4406-4412	select	_	_	_	_
27-54	4413-4422	potential	person[245]	new[245]	_	_
27-55	4423-4433	recipients	person[245]	new[245]	_	_
27-56	4434-4435	,	_	_	_	_
27-57	4436-4438	as	_	_	_	_
27-58	4439-4448	discussed	_	_	_	_
27-59	4449-4454	below	_	_	_	_
27-60	4455-4456	.	_	_	_	_
